[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].

Abstract

Sorafenib is a tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) used for advanced renal cell carcinoma. Treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal cell carcinoma. However, in spite of its therapeutic efficacy, sorafenib causes a wide range of adverse events. Cardiovascular adverse events have been observed when sorafenib was used with targeted agents. Although these adverse events like hypertension, reduced left ventricular ejection fraction, cardiac ischemia or infarction were manageable with standard medical therapies in most cases, some had a poor clinical outcome. We report three cases of acute myocardial infarction associated with sorafenib in patients with metastatic renal cell carcinoma.

• Authors: Kimiaki Takagi, Manabu Takai, Kei Kawata, Kengo Horie, Mina Kikuchi, Taku Kato, Kosuke Mizutani, Kensaku Seike, Tomohiro Tsuchiya, Mitsuru Yasuda, Shigeaki Yokoi, Masahiro Nakano, Hiroaki Ushikoshi, Tatsuhiko Miyazaki, Takashi Deguchi
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 61 Issue 9 Pg. 347-51 (Sep 2015) ISSN: 0018-1994 [Print] Japan
• PMID: 26497860 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Phenylurea Compounds
• Protein Kinase Inhibitors
• Niacinamide
• Sorafenib

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Carcinoma, Renal Cell (drug therapy)
• Humans
• Kidney Neoplasms (drug therapy)
• Male
• Middle Aged
• Molecular Targeted Therapy (adverse effects)
• Myocardial Infarction (chemically induced)
• Niacinamide (administration & dosage, adverse effects, analogs & derivatives)
• Phenylurea Compounds (administration & dosage, adverse effects)
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Sorafenib